Curidium Medica plc
("Curidium" or "the Company")
PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2007
LONDON, UK, 12 May 2008, Curidium Medica plc, (LSE : CUR ), the
personalised medicine company focused on bringing the right drug to the
right patient, announced today its Preliminary Results for the year ended
31 December 2007.
Financial highlights
Year ended Year ended
31 December 31 December
2007 2006
Research and Development expenditure GBP389,994 GBP304,712
Group Operating Loss GBP1,292,973 GBP976,558
Group Loss Before Tax GBP1,167,659 GBP945,036
Loss per Share 0.20p 0.24p
Cash out flow from operating
activities GBP1,276,104 GBP627,291
Operational highlights
* Signed partnership agreement with Takeda Research Investment
Inc. applying Homomatrix® to Major Depressive Disorder
* Raised GBP2.5 million in subscription agreement
* Trademarked "PsychINDx" as blood test for Schizophrenia (SZ)
/ Bipolar (BP) Disorder patient subgroups
* Discovered statistically significantly different patient
subgroups in SZ/BP Disorder
* Discovered unique Gene Expression Profiles in blood of SZ/BP
patient subgroups
Gosse Bruinsma, Executive Chairman of Curidium said:"This has been a
transformational year for Curidium in which its
proprietary technology Homomatrix® consecutively proved to identify the
statistically significant patient sub-groups, thereby proving the
technology strategy, the Balance Sheet was strengthened with a significant
fund raising in July 2007 and we signed a strategic research alliance with
Takeda Research which included a GBP1.25m investment."In 2008 overall
market conditions are encouraging with both regulatory
and 'pharmaco-economics' driving interest in effective personalised
medicine solutions. We have stepped up our marketing of PsychINDxTM to a
number of preferred partners and have received a favourable reception to
date. We continue to believe and drive towards our overriding company
objective: to bring theright drug to the right patient."
Click on the following link or paste into your browser to view the full
announcement:
http://www.rns-pdf.londonstockexchange.com/rns/4090U_1-2008-5-14.pdf
- Ends -
For further information please contact:
Gosse B. Bruinsma, M.D. +31 (0) 629 046 397
Executive Chairman, Curidium Medica plc
Rob Smith +44 (0) 20 7383 5345
Finance Director, Curidium Medica plc
Charlie Cunningham +44 (0) 20 7600 1658
FinnCap
Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113
Financial Dynamics
This information is provided by RNS
The company news service from the London Stock Exchange
END
Contact Information: For further information please contact: Gosse B. Bruinsma M.D. +31 (0) 629 046 397 Executive Chairman Curidium Medica plc Rob Smith +44 (0) 20 7383 5345 Finance Director Curidium Medica plc Charlie Cunningham +44 (0) 20 7600 1658 FinnCap Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113 Financial Dynamics